Long term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiency

J Clin Endocrinol Metab. 1988 Mar;66(3):611-7. doi: 10.1210/jcem-66-3-611.


We treated seven GH-deficient children with 3-hourly 1 microgram/kg sc pulses of GHRH-(1-44) for 6 months and 2 micrograms/kg.pulse for another 6 months. Four patients had a serum GH response to iv GHRH before treatment, and an additional patient responded to iv GHRH after 1 month of pulsatile sc GHRH administration. The mean cumulative growth velocity increased from a pretreatment mean of 2.7 +/- 0.2 (+/- SE) to 8.4 +/- 2.5 and 5.4 +/- 0.7 cm/yr after 2 months and 1 yr of treatment, respectively. Low dose pulsatile GHRH therapy was effective in promoting growth in five of seven children, with height gain ranging from 4.4-7.5 cm at the end of 1 yr's therapy. Only one of the two patients who did not respond to GHRH had an improvement in linear growth when they were subsequently treated with synthetic GH. The other patient, a 16.5-yr-old pubertal girl who had both satisfactory GH and somatomedin-C responses during GHRH therapy, did not respond to either GHRH or, later, synthetic GH. The pretreatment serum GH response to iv GHRH, the serum somatomedin-C concentrations, and the peak serum GH response during sc GHRH therapy were not reliable predictors of clinical response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Growth Disorders / blood
  • Growth Disorders / drug therapy*
  • Growth Hormone / blood
  • Growth Hormone / deficiency*
  • Growth Hormone-Releasing Hormone / administration & dosage
  • Growth Hormone-Releasing Hormone / therapeutic use*
  • Humans
  • Insulin-Like Growth Factor I / blood
  • Male


  • Insulin-Like Growth Factor I
  • Growth Hormone
  • Growth Hormone-Releasing Hormone